A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Pharmacokinetic equivalence of ANX-514 and Taxotere
No
Jeff Stewart, MBA
Study Director
Mast Therapeutics, Inc.
United States: Food and Drug Administration
ANX 514-01
NCT00664170
April 2008
April 2009
Name | Location |
---|---|
UCSD Moores Cancer Center | La Jolla, California 93093 |
Northwest Alabama Cancer Center | Muscle Shoals, Alabama 35661 |
Signal Point Hematology/Oncology Inc. | Middletown, Ohio 45042 |